Features
Excel add-in
New
PowerPoint add-in
New
Pricing
FAQ
Sign in
Sign up
Sign up
Low
Medium
High
Download PNG
Download SVG
Copy and edit
Revenue → Gross Profit: $7.09B
Diabetes → Revenue: $5.49B
Gross Profit → Operating cost: $4.59B
Operating cost → R&D: $2.52B
Gross Profit → Operating profit: $2.51B
Operating profit → Net Profit: $2.24B
Operating cost → Marketing, S&A: $1.95B
Oncology → Revenue: $1.81B
Mounjaro → Diabetes: $1.81B
Revenue → Cost of Revenue: $1.67B
Trulicity → Diabetes: $1.46B
Verzenio → Oncology: $1.05B
Immunology → Revenue: $0.83B
Jardiance → Diabetes: $0.69B
Taltz → Immunology: $0.60B
Humalog → Diabetes: $0.54B
Zepbound → Diabetes: $0.52B
Neuroscience → Revenue: $0.39B
Operating profit → Taxes: $0.29B
Other oncology → Oncology: $0.27B
Other → Revenue: $0.24B
Cyramza → Oncology: $0.23B
Emgality → Neuroscience: $0.23B
Olumiant → Immunology: $0.22B
Humulin → Diabetes: $0.21B
Other neuroscience → Neuroscience: $0.16B
Basaglar → Diabetes: $0.16B
Erbitux → Oncology: $0.14B
Cialis → Other: $0.14B
Other diabetes → Diabetes: $0.12B
Tyvyt → Oncology: $0.12B
Operating cost → Acquired IPR&D: $0.11B
Forteo → Other: $0.06B
Others → Other: $0.04B
Other income → Operating profit: $0.03B
Other immunology → Immunology: $0.01B
Revenue: $8.77B
Gross Profit: $7.09B
Operating profit: $2.54B
Operating cost: $4.59B
Net Profit: $2.24B
Taxes: $0.29B
Other income: $0.03B
Cost of Revenue: $1.67B
Marketing, S&A: $1.95B
Acquired IPR&D: $0.11B
R&D: $2.52B
Mounjaro: $1.81B
Diabetes: $5.49B
Trulicity: $1.46B
Jardiance: $0.69B
Humalog: $0.54B
Zepbound: $0.52B
Humulin: $0.21B
Basaglar: $0.16B
Other diabetes: $0.12B
Verzenio: $1.05B
Oncology: $1.81B
Cyramza: $0.23B
Erbitux: $0.14B
Tyvyt: $0.12B
Other oncology: $0.27B
Taltz: $0.60B
Immunology: $0.83B
Olumiant: $0.22B
Other immunology: $0.01B
Emgality: $0.23B
Neuroscience: $0.39B
Other neuroscience: $0.16B
Cialis: $0.14B
Other: $0.24B
Forteo: $0.06B
Others: $0.04B
created with SankeyArt.com
Revenue
$8.77B
26% Y/Y
Gross Profit
$7.09B
33% Y/Y
Operating profit
$2.54B
66% Y/Y
Operating cost
$4.59B
19% Y/Y
Net Profit
$2.24B
67% Y/Y
Taxes
$0.29B
59% Y/Y
Other income
$0.03B
Cost of Revenue
$1.67B
3% Y/Y
Marketing, S&A
$1.95B
12% Y/Y
Acquired IPR&D
$0.11B
5% Y/Y
R&D
$2.52B
27% Y/Y
Mounjaro
$1.81B
Diabetes
$5.49B
31% Y/Y
Trulicity
$1.46B
Jardiance
$0.69B
Humalog
$0.54B
Zepbound
$0.52B
Humulin
$0.21B
Basaglar
$0.16B
Other diabetes
$0.12B
Verzenio
$1.05B
Oncology
$1.81B
33% Y/Y
Cyramza
$0.23B
Erbitux
$0.14B
Tyvyt
$0.12B
Other oncology
$0.27B
Taltz
$0.60B
Immunology
$0.83B
7% Y/Y
Olumiant
$0.22B
Other immunology
$0.01B
Emgality
$0.23B
Neuroscience
$0.39B
8% Y/Y
Other neuroscience
$0.16B
Cialis
$0.14B
Other
$0.24B
-12% Y/Y
Forteo
$0.06B
Others
$0.04B
Eli Lilly Q1 FY24 Income Statement
